Roche stock: $570 million MediLink cancer-drug deal puts Swiss shares back in focus
Roche agreed to pay MediLink $570 million upfront and in near-term milestones for ex-China rights to experimental cancer drug YL201. Roche shares closed up 0.4% at 340.80 Swiss francs after the deal was announced. The Swiss SMI index hit a record high. Investors await Roche’s appearance at the JPM Healthcare Conference on Jan. 12 and its full-year earnings on Jan. 29.